Document Detail

Co-transplantation of islets with mesenchymal stem cells in microcapsules demonstrates graft outcome can be improved in an isolated-graft model of islet transplantation in mice.
MedLine Citation:
PMID:  23321331     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AIMS: Co-transplantation of islets with mesenchymal stem cells (MSCs) has been shown to improve graft outcome in mice, which has been partially attributed to the effects of MSCs on revascularization and preservation of islet morphology. Microencapsulation of islets provides an isolated-graft model of islet transplantation that is non-vascularized and prevents islet aggregation to preserve islet morphology. The aim of this study was to investigate whether MSCs could improve graft outcome in a microencapsulated/isolated-graft model of islet transplantation.
METHODS: Mouse islets and kidney MSCs were co-encapsulated in alginate, and their function was assessed in vitro. A minimal mass of 350 syngeneic islets encapsulated alone or co-encapsulated with MSCs (islet+MSC) were transplanted intraperitoneally into diabetic mice, and blood glucose concentrations were monitored. Capsules were recovered 6 weeks after transplantation, and islet function was assessed.
RESULTS: Islets co-encapsulated with MSCs in vitro had increased glucose-stimulated insulin secretion and content. The average blood glucose concentration of transplanted mice was significantly lower by 3 weeks in the islet+MSC group. By week 6, 71% of the co-encapsulated group were cured compared with 16% of the islet-alone group. Capsules recovered at 6 weeks had greater glucose-stimulated insulin secretion and insulin content in the islet+MSC group.
CONCLUSIONS: MSCs improved the efficacy of microencapsulated islet transplantation. Using an isolated-graft model, we were able to eliminate the impact of MSC-mediated enhancement of revascularization and preservation of islet morphology and demonstrate that the improvement in insulin secretion and content is sustained in vivo and can significantly improve graft outcome.
Alan Kerby; Edward S Jones; Peter M Jones; Aileen J King
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cytotherapy     Volume:  15     ISSN:  1477-2566     ISO Abbreviation:  Cytotherapy     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-16     Completed Date:  2013-09-04     Revised Date:  2014-11-05    
Medline Journal Info:
Nlm Unique ID:  100895309     Medline TA:  Cytotherapy     Country:  England    
Other Details:
Languages:  eng     Pagination:  192-200     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Glucose
Diabetes Mellitus, Experimental / therapy*
Insulin / secretion
Islets of Langerhans / pathology
Islets of Langerhans Transplantation*
Mesenchymal Stem Cell Transplantation*
Mesenchymal Stromal Cells / cytology*
Neovascularization, Physiologic*
Grant Support
11/0004290//Diabetes UK; BB/E527098/1//Biotechnology and Biological Sciences Research Council
Reg. No./Substance:
0/Blood Glucose; 0/Insulin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells.
Next Document:  Sildenafil improves long-term effect of endothelial progenitor cell-based treatment for monocrotalin...